Media headlines about Vital Therapies (NASDAQ:VTL) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.3031750004569 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of NASDAQ:VTL opened at $6.15 on Wednesday. Vital Therapies has a fifty-two week low of $2.42 and a fifty-two week high of $7.30. The stock has a market capitalization of $262.69 million, a PE ratio of -4.69 and a beta of 4.23.
Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.34) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.34). sell-side analysts expect that Vital Therapies will post -1.23 EPS for the current year.
A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 28th. BidaskClub raised shares of Vital Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, April 4th. Zacks Investment Research downgraded shares of Vital Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, March 17th. Finally, BTIG Research reissued a “hold” rating on shares of Vital Therapies in a research report on Monday, May 28th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold”.
Vital Therapies Company Profile
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.